Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer

NCT00349219 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT00349219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00349219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2006
Completion date
June 30, 2012
Enrollment
760 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer